DexCom (DC4) Stock Overview
A medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for DC4 from our risk checks.
DC4 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
DexCom, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$58.60 |
| 52 Week High | US$88.54 |
| 52 Week Low | US$47.00 |
| Beta | 1.49 |
| 1 Month Change | -2.75% |
| 3 Month Change | 14.99% |
| 1 Year Change | -30.25% |
| 3 Year Change | -45.46% |
| 5 Year Change | -31.84% |
| Change since IPO | 3,742.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| DC4 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -1.2% | -5.4% | 0.9% |
| 1Y | -30.2% | -30.5% | 4.9% |
Return vs Industry: DC4 matched the German Medical Equipment industry which returned -29.6% over the past year.
Return vs Market: DC4 underperformed the German Market which returned 7.3% over the past year.
Price Volatility
| DC4 volatility | |
|---|---|
| DC4 Average Weekly Movement | 4.2% |
| Medical Equipment Industry Average Movement | 5.4% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 13.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: DC4 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: DC4's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 10,250 | Jake Leach | www.dexcom.com |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators.
DexCom, Inc. Fundamentals Summary
| DC4 fundamental statistics | |
|---|---|
| Market cap | €21.12b |
| Earnings (TTM) | €705.34m |
| Revenue (TTM) | €3.93b |
Is DC4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DC4 income statement (TTM) | |
|---|---|
| Revenue | US$4.66b |
| Cost of Revenue | US$1.86b |
| Gross Profit | US$2.80b |
| Other Expenses | US$1.97b |
| Earnings | US$836.30m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.17 |
| Gross Margin | 60.10% |
| Net Profit Margin | 17.94% |
| Debt/Equity Ratio | 45.2% |
How did DC4 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/13 19:34 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DexCom, Inc. is covered by 49 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Johnson | Baird |
| Matthew Miksic | Barclays |
| Travis Steed | Barclays |